zirconium has been researched along with Esophageal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhanot, U; Biachi De Castria, T; Bojilova, V; Capanu, M; Ceglia, N; Chatila, W; Chou, JF; Do, RKG; Elzein, A; Feder, L; Hechtman, JF; Ilson, DH; Janjigian, YY; Kim, K; Ku, GY; Lee, J; Lewis, JS; Maron, SB; Merghoub, T; Nagy, RJ; Pandit-Taskar, N; Paroder, V; Ptashkin, R; Sabwa, S; Schultz, N; Schulze, I; Segal, M; Shah, S; Simmons, M; Socolow, F; Solit, DB; Thomas, J; Walch, H; Zatzman, M | 1 |
| Arjaans, M; de Vries, EG; Garbacik, ET; Gietema, JA; Lub-de Hooge, MN; Oosting, SF; Oude Munnink, TH; Schröder, CP; Terwisscha van Scheltinga, AG; Timmer-Bosscha, H | 1 |
1 trial(s) available for zirconium and Esophageal Neoplasms
| Article | Year |
|---|---|
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Esophageal Neoplasms; Female; Humans; Programmed Cell Death 1 Receptor; Radioisotopes; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Zirconium | 2023 |
1 other study(ies) available for zirconium and Esophageal Neoplasms
| Article | Year |
|---|---|
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Drug Interactions; Esophageal Neoplasms; Female; Humans; Immunoglobulin G; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Trastuzumab; Xenograft Model Antitumor Assays; Zirconium | 2013 |